Approved for use through 02/29/2008. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO	Complete if Known			
Sabalkale is folia 14431 10	Application Number	10/720,134		
INFORMATION DISCLOSURE	Filing Date	November 25, 2003		
STATEMENT BY APPLICANT	First Named Inventor	Thomas P. Jerussi		
(Use as many sheets as necessary)	Art Unit	1621		
(Use as many sneets as necessary)	Examiner Name	Paul A. Zucker		
Sheet 1 of 1	Attorney Docket Number	4821-531-999		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	1	Eric A. MUTH, et al., Clinical Experience with Effexor (Venlafaxine HCl): Meet the Experts, May 21, 1994, Philadelphia, PA		

Examiner		Date			
Signature		Considered			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not					

considered. Include copy of this form with next communication to applicant. considered. Include Coby of this torm was next communication to applicate.

1. Applicant's runny catched necessary to the communication of the communication

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.